Xenon Pharmaceuticals INC 8-K filings

Xenon Pharmaceuticals Inc. held its annual meeting on June 2, 2026, where shareholders approved the 2026 Equity Incentive Plan and elected directors.

Xenon Pharmaceuticals announced positive Q1 2026 financial results, highlighting strong cash reserves and significant progress in its late-stage clinical trials for azetukalner.

Xenon Pharmaceuticals Inc. has amended its 2025 Inducement Equity Plan to increase the share reserve for new hires and rehires.

Xenon Pharmaceuticals Inc. announced the key dates and logistics for its 2026 annual meeting of shareholders, scheduled for June 2, 2026.

Xenon Pharmaceuticals Inc. announced the closing of an underwritten public offering, raising approximately $707.7 million in net proceeds through the sale of common shares and pre-funded warrants.

Xenon Pharmaceuticals Inc. filed a prospectus supplement to register $400 million in common shares for its at-the-market equity offering program.

Xenon Pharmaceuticals announced its full year 2025 financial results and provided key updates on its azetukalner clinical programs and early-stage pipeline, with significant data readouts anticipated in early 2026 and 2027.

Xenon Pharmaceuticals Inc. increased the share reserve for its 2025 Inducement Equity Incentive Plan to 900,000 shares to attract and retain talent.

Xenon Pharmaceuticals announced its third-quarter 2025 financial results and provided a business update, highlighting progress in its late-stage azetukalner clinical programs and early-stage pipeline.

Xenon Pharmaceuticals Inc. announced the appointment of Thomas (Tucker) Kelly as its new Chief Financial Officer, effective October 15, 2025, bringing extensive commercialization experience.

Xenon Pharmaceuticals strengthens its executive team with the appointment of Tucker Kelly, an experienced biopharmaceutical CFO, as it prepares for potential drug commercialization.

Xenon Pharmaceuticals announced its second quarter 2025 financial results and provided a business update, highlighting significant progress in its azetukalner clinical programs and early-stage pipeline.

Xenon Pharmaceuticals Inc. announced that its President and Chief Executive Officer, Ian Mortimer, has been appointed interim Chief Financial Officer following the resignation of Sherry Aulin, effective June 30, 2025.

Xenon Pharmaceuticals Inc. announced that all four proposals, including the election of directors, executive compensation, and auditor appointments, were approved by shareholders at its 2025 Annual Meeting.

Xenon Pharmaceuticals announced its Q1 2025 financial results and provided a business update, highlighting progress in its Phase 3 epilepsy program and advancements in neuropsychiatry and early-stage programs.

Xenon Pharmaceuticals has announced the date, record date, and other pertinent information regarding its 2025 annual meeting of shareholders.

Xenon Pharmaceuticals has dismissed KPMG as its independent auditor and appointed PricewaterhouseCoopers (PwC) in its place, effective for the fiscal year ending December 31, 2025.

Xenon Pharmaceuticals announces its full year 2024 financial results, highlights clinical program advancements, and anticipates a catalyst-rich period with multiple regulatory filings.

Xenon Pharmaceuticals' Chief Commercial Officer, Christopher Von Seggern, has departed the company, effective January 17, 2025, with a separation and consulting agreement in place.

Xenon Pharmaceuticals announced its Q3 2024 financial results and provided a business update, highlighting the progress of its epilepsy and depression programs.

Xenon Pharmaceuticals announced its Q2 2024 financial results and provided a business update, highlighting progress in its epilepsy and major depressive disorder (MDD) programs.

Xenon Pharmaceuticals successfully held its 2024 Annual Meeting of Shareholders, with all proposed resolutions being approved, including the election of directors and amendments to the equity plan.

Xenon Pharmaceuticals announced its first quarter 2024 financial results and provided updates on its clinical programs, including the progress of its Phase 3 epilepsy trials and the planned initiation of a Phase 3 program for major depressive disorder.

Xenon Pharmaceuticals announces that two board members, including the chair, will not seek re-election at the upcoming 2024 annual meeting.

Xenon Pharmaceuticals has set the date for its 2024 annual shareholder meeting for June 4, 2024, with a record date of April 5, 2024.

Xenon Pharmaceuticals announced its full year 2023 financial results, highlighted by progress in its XEN1101 clinical programs and a strong cash position.